Molecular Partners AG/ CH0256379097 /
| 2024-06-07 3:55:48 PM | Chg. -0.05 | Volume | Bid4:38:41 PM | Ask4:40:13 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 3.79CHF | -1.30% | 940 Turnover: 3,562.60 |
3.65Bid Size: 416 | 3.76Ask Size: 306 | 134.51 mill.CHF | - | - |
GlobeNewswire
06-01
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin)...
GlobeNewswire
05-16
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional...
GlobeNewswire
04-29
Molecular Partners Announces Publication in Cancer Immunology Research of Preclinical Data Supportin...
GlobeNewswire
04-17
Molecular Partners Announces All Board Proposals Approved at the Annual General Meeting
GlobeNewswire
03-14
Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023
GlobeNewswire
03-01
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and ...
GlobeNewswire
01-07
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire
01-05
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
GlobeNewswire
2023-12-14
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Co...
GlobeNewswire
2023-12-10
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/...
GlobeNewswire
2023-11-14
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summi...
GlobeNewswire
2023-11-03
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) ...
GlobeNewswire
2023-11-02
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with...
GlobeNewswire
2023-11-01
Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
GlobeNewswire
2023-10-26
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin...
GlobeNewswire
2023-09-13
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Ann...
GlobeNewswire
2022-03-24
Molecular Partners Announces Publication of Preclinical Data from CD40 Therapeutic Candidate MP0317 ...
GlobeNewswire
2022-03-15
Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021
